Compare PRME & BLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRME | BLND |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.2M | 352.4M |
| IPO Year | 2022 | 2021 |
| Metric | PRME | BLND |
|---|---|---|
| Price | $3.23 | $1.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $7.56 | $4.13 |
| AVG Volume (30 Days) | 2.5M | ★ 2.5M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 58.33 |
| EPS | N/A | ★ N/A |
| Revenue | $4,632,000.00 | ★ $123,585,000.00 |
| Revenue This Year | $7.06 | $12.62 |
| Revenue Next Year | $47.01 | $14.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $2.67 | $1.18 |
| 52 Week High | $6.94 | $4.49 |
| Indicator | PRME | BLND |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 40.37 |
| Support Level | $3.16 | $1.38 |
| Resistance Level | $3.32 | $1.67 |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 60.80 | 13.19 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.